zurück

Doravirine (new indication: HIV infection, patients aged 12 to < 18 years)


Subject:

  • Active Substance: Doravirine
  • Name: Pifeltro®
  • Therapeutic area: HIV infection
  • Pharmaceutical company: MSD Sharp & Dohme GmbH


Time table:

  • Start: 01.05.2022
  • Final decision by G-BA: 20.10.2022


Final decision:

  • Treatment-naïve adolescents: No additional benefit proved
  • Treatment-experienced adolescents: No additional benefit proved